Medications for Cognitive Decline: What Caregivers Need to Know About Dementia Drugs

When a parent is diagnosed with dementia or mild cognitive impairment, the question about medications comes up quickly: Is there something they can take that will help? The honest answer is more complicated than either a reassuring yes or a dismissive no. Medications for cognitive decline do exist, they do work — but with specific mechanisms, specific populations, and specific limitations that most families are not told clearly.

This guide covers the current standard of care for dementia pharmacotherapy, the newer disease-modifying drugs that have recently become available, and what caregivers need to understand about managing these medications day-to-day.

Two Categories of Dementia Medication

Dementia medications fall into two fundamentally different categories:

Symptomatic drugs work by compensating for the neurotransmitter deficiencies that dementia causes. They do not alter the underlying disease process. They can improve function, slow the rate of functional decline, and manage behavioral symptoms — but the disease continues to progress.

Disease-modifying drugs are a newer category that targets the biological processes driving Alzheimer's disease itself — specifically amyloid beta plaque accumulation. These drugs aim to slow the progression of the underlying disease, not just manage symptoms.

Most patients with Alzheimer's are eligible for symptomatic treatment. Disease-modifying treatment currently applies to a narrower population in the early stages of the disease.

Cholinesterase Inhibitors: The Most Commonly Prescribed Class

Cholinesterase inhibitors are the first-line pharmacological treatment for Alzheimer's disease and are also used in Lewy body dementia and Parkinson's-related dementia.

The mechanism: Alzheimer's disease destroys the neurons that produce acetylcholine, a neurotransmitter critical for memory and learning. Cholinesterase inhibitors block the enzyme (acetylcholinesterase) that breaks down acetylcholine, allowing the remaining acetylcholine to work more effectively for longer.

Three approved cholinesterase inhibitors:

Donepezil (Aricept): The most widely prescribed. Available in 5mg and 10mg oral tablets, and a 23mg tablet for moderate-to-severe Alzheimer's. Also available as an orally disintegrating tablet for patients with swallowing difficulty. Once-daily dosing makes adherence manageable.

Rivastigmine (Exelon): Available as oral capsules and as a transdermal patch. The patch is particularly useful when a parent has swallowing difficulty, nausea with oral dosing, or inconsistent oral adherence (the patch is applied and visible, making missed doses easier to catch). Inhibits both acetylcholinesterase and butyrylcholinesterase — the dual inhibition may provide additional benefit in Lewy body dementia.

Galantamine (Razadyne): Available in immediate-release (twice daily) and extended-release (once daily) formulations. Has an additional mechanism of enhancing nicotinic receptor activity. Less commonly prescribed than donepezil, but clinically equivalent.

What the evidence shows: Cholinesterase inhibitors produce modest but real improvement in cognitive test scores and clinically meaningful stabilization of function in approximately 40–50% of patients who tolerate them. In responders, the benefit is most visible as a plateau in functional decline rather than as visible improvement — which is why many families feel the drugs are "not doing anything" when they are actually preventing faster deterioration.

Common side effects: Nausea, vomiting, diarrhea, and decreased appetite are the most common and typically occur in the first weeks of treatment. Slower dose titration (starting at 5mg donepezil and increasing to 10mg after 4–6 weeks rather than immediately) significantly reduces GI side effects. Bradycardia (slow heart rate) is a less common but important cardiac effect — mention any existing cardiac conditions or pacemakers to the prescribing doctor.

What to tell the doctor: Report nausea and GI symptoms within the first month — they are often manageable with dose adjustment or formulation change (switching to the rivastigmine patch) rather than discontinuation.

Memantine (Namenda): For Moderate to Severe Stages

Memantine works through a completely different mechanism from cholinesterase inhibitors. It blocks NMDA receptors and reduces excessive glutamate activity, which causes neural damage in moderate to severe Alzheimer's.

Approved for: Moderate to severe Alzheimer's disease (MMSE score below 20). Not indicated for mild Alzheimer's.

Formulations: Immediate-release (twice daily) and extended-release (once daily). Extended-release is preferred for adherence.

Use in combination: Memantine is commonly prescribed alongside a cholinesterase inhibitor (particularly donepezil) for patients with moderate to severe disease. The combination Namzaric (donepezil + memantine extended-release in a single capsule) simplifies this regimen to one pill daily.

Side effects: Generally well tolerated. Most common: dizziness, headache, and constipation. Serious side effects are uncommon.

Realistic expectations: Memantine slows functional decline and manages agitation in moderate to severe stages. It does not reverse cognitive loss.

Disease-Modifying Drugs: A New and Evolving Category

The most significant development in dementia pharmacotherapy in decades is the FDA approval of two anti-amyloid monoclonal antibodies: lecanemab (Leqembi) and donanemab (Kisunla). These are disease-modifying drugs — they target amyloid beta, the protein that accumulates in the brains of people with Alzheimer's, and have demonstrated slowing of clinical decline in clinical trials.

Lecanemab (Leqembi): FDA-approved in 2023. Clinical trials showed a 27% slowing of cognitive decline on standardized scales at 18 months compared to placebo.

Donanemab (Kisunla): FDA-approved in 2024. Trial data showed approximately 35% slowing of decline in early-stage patients.

These are meaningful results — a one-third slowing of decline is clinically significant. However, several important caveats apply:

They are only for early-stage disease. Both drugs are indicated for mild cognitive impairment or mild Alzheimer's dementia with confirmed amyloid pathology. They are not appropriate for — and have not been tested in — moderate or severe Alzheimer's patients.

Amyloid confirmation is required. Patients must have a PET scan or cerebrospinal fluid test confirming amyloid pathology before starting treatment. These tests are not universally covered and require specialized memory centers.

They are IV infusions. Neither drug is a pill. Lecanemab is administered intravenously every two weeks; donanemab was given monthly in trials. This requires regular clinic visits.

Serious risks exist. Both drugs cause ARIA (Amyloid-Related Imaging Abnormalities) — brain swelling or bleeding visible on MRI — in a significant proportion of patients. Most ARIA is asymptomatic and detected on monitoring MRIs, but serious symptomatic ARIA occurs in 2–3% of patients. Patients on blood thinners face higher ARIA risk. Regular MRI monitoring is required during treatment.

Cost and access barriers. As of 2026, these drugs cost approximately $26,000–$32,000 per year. Medicare covers them in many situations, but the access pathway is complex and requires specialist referral.

Who should discuss these drugs with their doctor: Families with a parent who has been recently diagnosed with mild cognitive impairment or early Alzheimer's disease, is otherwise in reasonable health, is not on high-dose blood thinners (which significantly increase ARIA risk), and has access to a memory center capable of providing the required monitoring.

Medications Used for Behavioral Symptoms of Dementia

As dementia progresses, behavioral symptoms often emerge: agitation, aggression, psychosis (paranoia, hallucinations), sleep disturbance, and depression. These are frequently more distressing to caregivers than the cognitive decline itself and are the most common reason for nursing home placement.

Non-drug approaches should always be tried first. Environmental modifications, structured routine, caregiver communication techniques, and identifying underlying triggers (pain, urinary tract infection, medication side effects) resolve many behavioral episodes without drugs. The Alzheimer's Association's DICE approach (Describe, Investigate, Create, Evaluate) is the evidence-based framework for behavioral management.

When medications are necessary:

For psychosis and severe agitation: Atypical antipsychotics (quetiapine/Seroquel, risperidone, olanzapine) are commonly used, but carry a black box FDA warning for increased mortality risk in elderly patients with dementia. They should be used at the lowest effective dose for the shortest necessary time, with regular reassessment for discontinuation. Quetiapine tends to be preferred for its lower EPS risk and relative sedation profile.

For agitation: Citalopram has evidence for reducing agitation in Alzheimer's patients at doses lower than those used for depression. Pimavanserin (Nuplazid) has a narrower FDA indication for Parkinson's-related psychosis but is sometimes considered off-label for other dementia-related psychosis.

For sleep: Low-dose melatonin (0.5–1mg) is the safest first-line option for sleep disruption in dementia. Avoid diphenhydramine (Benadryl, Tylenol PM) — its anticholinergic mechanism is directly harmful in a brain already depleted of acetylcholine. Suvorexant (Belsomra) is an orexin antagonist with some evidence in Alzheimer's-related sleep disruption.

For depression: SSRIs are first-line. Sertraline and citalopram are well-tolerated in elderly patients with dementia.

What Caregivers Need to Track

Managing a parent on dementia medications requires close tracking, because the signals that a medication is or is not working are subtle:

Baseline documentation. Before starting any dementia medication, document your parent's current functional status: what they can do independently, what they can do with assistance, and what specific behavioral symptoms are present. Without a baseline, it is impossible to assess whether a drug is helping.

Effect timeline. Cholinesterase inhibitors require four to six weeks to reach stable levels and may take twelve weeks before benefit is noticeable. Do not discontinue for perceived ineffectiveness within the first month.

Behavioral symptom log. For parents with agitation or psychosis, keeping a daily log of episode frequency, severity, and context makes medication adjustments more evidence-based. It also helps distinguish medication side effects from disease progression.

All medications on one list. Dementia patients are often on multiple medications for other conditions. Every drug your parent takes for any reason needs to be on the complete medication list that every prescriber sees — because many common medications (anticholinergics, sedatives, some antihistamines) significantly worsen cognitive function and can counteract dementia medications.

The Medication Management Kit includes a behavioral symptom tracking template, a complete medication record format, and an appointment preparation guide for dementia medication review conversations — giving caregivers the documentation structure needed to manage one of the most complex medication environments in elder care.